Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target boosted by analysts at Morgan Stanley from $473.00 to $476.00 in a note issued to investors on Tuesday, Benzinga reports.

This page features the latest news about the Vertex Pharmaceuticals DRC stock. Vertex Pharma to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective ...

HOUSTON, October 09, 2024--(BUSINESS WIRE)--Vertex Energy, Inc. (OTCPK:VTNRQ) ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...